Loading patent…
AssigneeIcahn School of Medicine at Mount Sinai
InventorsBo CHEN, Xinzheng GUO
Estimating the term…
A method of decreasing degeneration of retinal ganglion cells in a subject is provided, including administering to the subject a composition to increase activity of a calcium-calmodulin dependent kinase (CaMK) or cyclic-AMP response element-binding protein (CREB), wherein the composition comprises the CaMK or CREB or a polynucleotide encoding the CaMK or the CREB. Also provided is a method for treating vision loss in a subject is provided, including administering to the subject a composition to increase activity of a CaMK or CREB, wherein the composition comprises the CaMK or CREB or a polynucleotide encoding the CaMK or the CREB. Also provided is a pharmaceutical composition, including a polynucleotide and a vector, wherein the polynucleotide includes a retinal ganglion cell promoter and encodes a CaMK or CREB.
A method of decreasing degeneration of retinal ganglion cells in a subject, comprising
A method of treating vision loss in a subject, comprising
A pharmaceutical composition, comprising
A method of decreasing degeneration of retinal ganglion cells in a subject, comprising
A method of treating vision loss in a subject, comprising administering to the subject a composition to increase activity of a cyclic-AMP response element-binding protein (CREB) activity, wherein the composition comprises the CREB or a polynucleotide encoding the CREB.
A pharmaceutical composition, comprising
Dependencies are inferred from the claim text.